EcoR1 Capital, LLC 13D and 13G filings for iTeos Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-16 7:22 pm Purchase | 2025-05-15 | 13D | iTeos Therapeutics, Inc. ITOS | EcoR1 Capital, LLC | 10,688,978 27.900% | 4,958,978 (+86.54%) | Filing |
| 2025-05-13 7:10 pm Purchase | 2025-05-13 | 13G | iTeos Therapeutics, Inc. ITOS | EcoR1 Capital, LLC | 5,730,000 14.900% | 3,073,360 (+115.69%) | Filing |
| 2025-05-08 7:43 pm Purchase | 2025-05-01 | 13G | iTeos Therapeutics, Inc. ITOS | EcoR1 Capital, LLC | 2,656,640 6.900% | 1,048,024 (+65.15%) | Filing |
| 2024-11-14 6:04 pm Sale | 2024-09-30 | 13G | iTeos Therapeutics, Inc. ITOS | EcoR1 Capital, LLC | 1,608,616 4.400% | -336,056 (-17.28%) | Filing |
| 2024-02-16 12:54 pm Purchase | 2024-02-05 | 13G | iTeos Therapeutics, Inc. ITOS | EcoR1 Capital, LLC | 1,944,672 5.400% | 1,944,672 (New Position) | Filing |